XTL Biopharmaceutica Fundamental Relationships

XTLB -- Israel Stock  

ILS 8.30  0.40  4.60%

The Drivers Module shows relationships between XTL Biopharmaceutica's most relevant fundamental drivers and provides multiple suggestions of what could possibly affect the performance of XTL Biopharmaceuticals Ltd over time as well as its relative position and ranking within its peers. See also Your Current Watchlist

XTL Biopharmaceuticals Current Valuation vs. Cash per Share Fundamental Analysis

XTL Biopharmaceuticals Ltd is rated below average in cash per share category among related companies. It is rated below average in current valuation category among related companies reporting about  4,086,000,000  of Current Valuation per Cash per Share.
Cash per Share is a ratio of current cash on hands or in the banks of the company to total number of shares outstanding. It is used to determine firm's liquidity and is a good indicator of overall financial health of a company. Value investors often compare this ratio to the current stock quote, and if it exceeds the stock price they would invest in it.
XTL Biopharmaceutica 
Cash per Share 
 = 
Total Cash 
Average Shares 
=
0.01X
Companies with high Cash per Share ratio will be considered as attractive investment by most investors. In most industries if you can single out an equity instrument trading below its cash per share value, you have a bargain and should consider buying it. Finding the stocks traded below their cash value, therefore, can be a good starting point for investors using strategies based on fundamentals
Enterprise Value is a firm valuation proxy that approximates current market value of a company. It is typically used to determine takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that company has on its balance sheet. When takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
XTL Biopharmaceutica 
Enterprise Value 
 = 
Market Cap + Debt 
-  
Cash 
=
40.86M
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
  Revenue 
      XTL Biopharmaceutica Comparables 
XTL Biopharmaceutica is currently under evaluation in revenue category among related companies.
Search macroaxis.com